GlassScriptPhysician profile
Adity Dutta
NPI 1134748320
$5,633.61
in general payments reported to CMS, 2019-2025
34 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what 87% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.55 · 2022: $2,805 · 2023: $807 · 2024: $797 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,712 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,711.91 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $2,052.45 | 2022-2024 | Bulkamid |
| Boston Scientific Corporation | $463.36 | 2022-2025 | Ams 700, Lithovue, General - Erectile Dysfunction |
| Bayer Healthcare Pharmaceuticals INC. | $458.35 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $250.48 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $212.57 | 2022-2025 | |
| Janssen Biotech, INC. | $193.02 | 2022-2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $176.90 | 2023-2025 | Provenge |
| Calyxo, INC. | $176.71 | 2025 | Cvac Aspiration System |
| Myovant Sciences INC. | $175.98 | 2022 | |
| Myriad Genetic Laboratories, INC. | $134.97 | 2023-2025 | Prolaris |
| Astellas Pharma US INC | $112.83 | 2022-2025 | Xtandi |
| Merck Sharp & Dohme LLC | $102.86 | 2021-2024 | Lynparza |
| Endo Pharmaceuticals INC. | $99.13 | 2022-2024 | Aveed, Xiaflex |
| Procept Biorobotics Corporation | $98.21 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Vertex Pharmaceuticals Incorporated | $89.26 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $88.37 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $81.58 | 2022-2024 | Lynparza |
| Olympus America INC. | $73.42 | 2022-2024 | Itind System |
| Tolmar Pharmaceuticals, INC. | $72.85 | 2022 | |
| Tolmar, INC. | $70.23 | 2023-2024 | |
| Abbvie INC. | $58.61 | 2023-2024 | |
| Tempus Ai, INC | $56.61 | 2024 | |
| Coloplast Corp | $49.46 | 2024 | |
| Ferring Pharmaceuticals INC. | $43.87 | 2025 | Adstiladrin |
| Halozyme INC | $38.04 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $33.87 | 2023 | Seglentis |
| Medtronic, INC. | $28.95 | 2025 | Interstim |
| Endo USA, INC. | $26.62 | 2025 | Xiaflex |
| Novartis Pharmaceuticals Corporation | $22.50 | 2025 | |
| Sun Pharmaceutical Industries INC. | $22.20 | 2022 | |
| Civco Medical Instruments | $19.82 | 2024 | |
| Antares Pharma, INC. | $18.60 | 2023 | Tlando, Xyosted, Nocdurna |
| Baxter Healthcare | $17.09 | 2022 | |
| Progenics Pharmaceuticals, INC. | $13.84 | 2023 | Pylarify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adity Dutta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.